126 related articles for article (PubMed ID: 37334763)
1. Prenatal and pre-implantation genetic testing for monogenic disorders for germline cancer susceptibility gene variants: UK joint consensus guidance.
Wafik M; Kilby MD; Kulkarni A;
BJOG; 2023 Dec; 130(13):1563-1567. PubMed ID: 37334763
[No Abstract] [Full Text] [Related]
2. Co-design of patient information leaflets for germline predisposition to cancer: recommendations for clinical practice from the UK Cancer Genetics Group (UKCGG), Cancer Research UK (CRUK) funded CanGene-CanVar Programme and the Association of Genetic Nurse Counsellors (AGNC).
Kohut K; Speight B; Young J; Way R; Wiggins J; Monje-Garcia L; Eccles DM; Foster C; Turner L; Snape K; Hanson H; ;
J Med Genet; 2024 Jan; 61(2):142-149. PubMed ID: 38050080
[TBL] [Abstract][Full Text] [Related]
3. Germline Testing for the Evaluation of Hereditary Cancer Predisposition.
Ceyhan-Birsoy O
Clin Lab Med; 2022 Sep; 42(3):497-506. PubMed ID: 36150826
[TBL] [Abstract][Full Text] [Related]
4. UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes:
Hanson H; Kulkarni A; Loong L; Kavanaugh G; Torr B; Allen S; Ahmed M; Antoniou AC; Cleaver R; Dabir T; Evans DG; Golightly E; Jewell R; Kohut K; Manchanda R; Murray A; Murray J; Ong KR; Rosenthal AN; Woodward ER; Eccles DM; Turnbull C; Tischkowitz M; ; Lalloo F
J Med Genet; 2023 May; 60(5):417-429. PubMed ID: 36411032
[TBL] [Abstract][Full Text] [Related]
5. British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for
Sundar S; Manchanda R; Gourley C; George A; Wallace A; Balega J; Williams S; Wallis Y; Edmondson R; Nicum S; Frost J; Attygalle A; Fotopoulou C; Bowen R; Bell D; Gajjar K; Ramsay B; Wood NJ; Ghaem-Maghami S; Miles T; Ganesan R
Int J Gynecol Cancer; 2021 Feb; 31(2):272-278. PubMed ID: 33468564
[TBL] [Abstract][Full Text] [Related]
6. Risk-reducing surgery for individuals with cancer-predisposing germline pathogenic variants and no personal cancer history: a review of current UK guidelines.
McCarthy RL; Copson E; Tapper W; Bolton H; Mirnezami AH; O'Neill JR; Patel NN; Tischkowitz M; Cutress RI
Br J Cancer; 2023 Aug; 129(3):383-392. PubMed ID: 37258796
[TBL] [Abstract][Full Text] [Related]
7. Use of Treatment-Focused Tumor Sequencing to Screen for Germline Cancer Predisposition.
Lau TTY; May CM; Sefid Dashti ZJ; Swanson L; Starks ER; Parker JDK; Moore RA; Tucker T; Bosdet I; Young SS; Santos JL; Compton K; Heidary N; Hoang L; Schrader KA; Sun S; Kwon JS; Tinker AV; Karsan A
J Mol Diagn; 2021 Sep; 23(9):1145-1158. PubMed ID: 34197922
[TBL] [Abstract][Full Text] [Related]
8. Germline pathogenic variants in cancer risk genes among patients with thyroid cancer and suspected predisposition.
Kamihara J; Zhou J; LaDuca H; Wassner AJ; Dalton E; Garber JE; Black MH
Cancer Med; 2022 Apr; 11(8):1745-1752. PubMed ID: 35174967
[TBL] [Abstract][Full Text] [Related]
9. Germline Cancer Susceptibility Gene Testing in Unselected Patients with Hepatobiliary Cancers: A Multi-Center Prospective Study.
Uson Junior PL; Kunze KL; Golafshar MA; Riegert-Johnson D; Boardman L; Borad MJ; Ahn D; Sonbol MB; Faigel DO; Fukami N; Pannala R; Barrus K; Mountjoy L; Esplin ED; Nussbaum RL; Stewart AK; Bekaii-Saab T; Samadder NJ
Cancer Prev Res (Phila); 2022 Feb; 15(2):121-128. PubMed ID: 34782326
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing.
Terraf P; Pareja F; Brown DN; Ceyhan-Birsoy O; Misyura M; Rana S; O'Reilly E; Carlo MI; Aghajanian C; Liu Y; Derakhshan F; Jayakumaran G; Weigelt B; Walsh M; Stadler Z; Offit K; Ladanyi M; Robson M; Zehir A; Reis-Filho JS; Mandelker D
Ann Oncol; 2022 Apr; 33(4):426-433. PubMed ID: 35074424
[TBL] [Abstract][Full Text] [Related]
11. When to use germline genetic testing in prostate cancer.
Giri VN
Clin Adv Hematol Oncol; 2022 Feb; 20(2):78-81. PubMed ID: 35120087
[No Abstract] [Full Text] [Related]
12. Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer.
Whitworth PW; Beitsch PD; Patel R; Rosen B; Compagnoni G; Baron PL; Simmons R; Brown EA; Gold L; Holmes D; Smith LA; Kinney M; Grady I; Clark P; Barbosa K; Lyons S; Riley L; Coomer C; Curcio L; Ruiz A; Khan S; MacDonald H; Hughes K; Hardwick MK; Heald B; Munro SB; Nielsen SM; Esplin ED
JAMA Netw Open; 2022 Sep; 5(9):e2232787. PubMed ID: 36136330
[TBL] [Abstract][Full Text] [Related]
13. Germline pathogenic variants in unselected Korean men with prostate cancer.
So MK; Ahn HK; Huh J; Kim KH
Investig Clin Urol; 2022 May; 63(3):294-300. PubMed ID: 35534218
[TBL] [Abstract][Full Text] [Related]
14. Germline predisposition to haematological malignancies: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working Group.
Speight B; Hanson H; Turnbull C; Hardy S; Drummond J; Khorashad J; Wragg C; Page P; Parkin NW; Rio-Machin A; Fitzgibbon J; Kulasekararaj AG; Hamblin A; Talley P; McVeigh TP; Snape K;
Br J Haematol; 2023 Apr; 201(1):25-34. PubMed ID: 36744544
[TBL] [Abstract][Full Text] [Related]
15. Management of patients with germline predisposition to haematological malignancies considered for allogeneic blood and marrow transplantation: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar, NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group and the British Society of Blood and Marrow Transplantation and cellular therapy (BSBMTCT).
Clark A; Thomas S; Hamblin A; Talley P; Kulasekararaj A; Grinfeld J; Speight B; Snape K; McVeigh TP; Snowden JA
Br J Haematol; 2023 Apr; 201(1):35-44. PubMed ID: 36786081
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma.
Brand R; Borazanci E; Speare V; Dudley B; Karloski E; Peters MLB; Stobie L; Bahary N; Zeh H; Zureikat A; Hogg M; Lee K; Tsung A; Rhee J; Ohr J; Sun W; Lee J; Moser AJ; DeLeonardis K; Krejdovsky J; Dalton E; LaDuca H; Dolinsky J; Colvin A; Lim C; Black MH; Tung N
Cancer; 2018 Sep; 124(17):3520-3527. PubMed ID: 30067863
[TBL] [Abstract][Full Text] [Related]
17. Germline testing and genetic counselling in prostate cancer.
Russo J; Giri VN
Nat Rev Urol; 2022 Jun; 19(6):331-343. PubMed ID: 35449224
[TBL] [Abstract][Full Text] [Related]
18. Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer.
Gheybi K; Jiang J; Mutambirwa SBA; Soh PXY; Kote-Jarai Z; Jaratlerdsiri W; Eeles RA; Bornman MSR; Hayes VM
J Natl Compr Canc Netw; 2023 Mar; 21(3):289-296.e3. PubMed ID: 36898365
[TBL] [Abstract][Full Text] [Related]
19. Speaking genomics to parents offered germline testing for cancer predisposition: Use of a 2-visit consent model.
Johnson LM; Sykes AD; Lu Z; Valdez JM; Gattuso J; Gerhardt E; Hamilton KV; Harrison LW; Hines-Dowell SJ; Jurbergs N; McGee RB; Nuccio R; Ouma AA; Pritchard M; Quinn EA; Baker JN; Mandrell BN; Nichols KE
Cancer; 2019 Jul; 125(14):2455-2464. PubMed ID: 30901077
[TBL] [Abstract][Full Text] [Related]
20. Germline variants of Brazilian women with breast cancer and detection of a novel pathogenic ATM deletion in early-onset breast cancer.
Bandeira G; Rocha K; Lazar M; Ezquina S; Yamamoto G; Varela M; Takahashi V; Aguena M; Gollop T; Zatz M; Passos-Bueno MR; Krepischi A; Okamoto OK
Breast Cancer; 2021 Mar; 28(2):346-354. PubMed ID: 32986223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
